Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.

被引：0
|
作者：
Tripathi, Abhishek
Xie, Wanling
Sweeney, Christopher
Choudhury, Atish Dipankar
Pomerantz, Mark
Wei, Xiao X.
Taplin, Mary-Ellen
Choueiri, Toni K.
Lee, Gwo-Shu Mary
Kantoff, Philip W.
Harshman, Lauren Christine
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e17027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17027
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel
    Ahmet Taner Sümbül
    Ahmet Sezer
    Hüseyin Abalı
    Fatih Köse
    İlhami Gültepe
    Hüseyin Mertsoylu
    Sadık Muallaoğlu
    Özgür Özyılkan
    International Urology and Nephrology, 2014, 46 : 1531 - 1535
  • [42] The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients
    Chew, Sin-Chi
    Singh, Onkar
    Chen, Xiangai
    Ramasamy, Rathi Devi
    Kulkarni, Tejal
    Lee, Edmund J. D.
    Tan, Eng-Huat
    Lim, Wan-Teck
    Chowbay, Balram
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1471 - 1478
  • [43] Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel
    Sumbul, Ahmet Taner
    Sezer, Ahmet
    Abali, Huseyin
    Kose, Fatih
    Gultepe, Ilhami
    Mertsoylu, Huseyin
    Muallaoglu, Sadik
    Ozyilkan, Ozgur
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2014, 46 (08) : 1531 - 1535
  • [44] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
    Chi, Kim N.
    San Kheoh, Thian
    Ryan, Charles J.
    Molina, Arturo
    Bellmunt, Joaquim
    Vogelzang, Nicholas J.
    Rathkopf, Dana E.
    Fizazi, Karim
    Kantoff, Philip W.
    Li, Jinhui
    De Bono, Johann Sebastian
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial
    Chatta, G. S.
    Feinstein, T. M.
    Appleman, L. J.
    Friedland, D. M.
    Jacobs, S. A.
    Evans, T. L.
    Earle, M. F.
    Strausser, H. M.
    Gooding, W. E.
    Lenzner, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Impact of cabazitaxel on metastatic bone health in patients with castration resistant prostate cancer previously treated with docetaxel: CaBone Study.
    Santini, Daniele
    Morelli, Franco
    Bertoldo, Francesco
    Facchini, Gaetano
    Rizzi, Daniele
    Gatti, Davide
    Maiello, Evaristo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] Use of germ-line single nucleotide polymorphisms (SNPs) in drug transporters (ABCG2/ABCB1) and tubulin (TUBB4) to predict survival in patients with metastatic castrate-resistant prostate cancer (CRPC) receiving docetaxel
    Hahn, N. M.
    Jung, J.
    Philips, S.
    Patel, Y. R.
    Carr, K. A.
    Mohammadi, Y.
    Magjuka, D.
    Li, L.
    Sweeney, C.
    Skaar, T. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [48] Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone plus /- bevacizumab (B)
    Ryan, C. J.
    Dutta, S.
    Kelly, W.
    Morris, M. J.
    Taplin, M-E.
    Halabi, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 283 - 283
  • [49] The effects of SLCO1B3, ABCG2, MDR1, and CYP3A5 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxed in nasopharyngeal carcinoma patients.
    Chew, S.
    Li, H.
    Singh, O.
    Lim, W. T.
    Tan, E.
    Lee, J.
    Chowbay, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] POLYMORPHISMS OF ANDROGEN TRANSPORTING GENE SLCO1B3 AND SLCO2B1 MAY PARTICIPATE IN HORMONE-RESISTANCE AND ETHNIC DIFFERENCE IN RESPONSE OF PROSTATE CANCER TO ANDROGEN DEPRIVATION THERAPY
    Fujimoto, Naohiro
    Kubo, Tatsuhiko
    Bui, Hoai
    Tomisaki, Ikko
    Matsumoto, Tetsuro
    JOURNAL OF UROLOGY, 2013, 189 (04): : E392 - E392
12345